enGene Holdings Inc. (NASDAQ:ENGNW) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGNW) was the recipient of a large decrease in short interest in the month of February. As of February 27th, there was short interest totaling 7,709 shares, a decrease of 21.7% from the February 12th total of 9,849 shares. Based on an average trading volume of 3,318 shares, the short-interest ratio is presently 2.3 days. Based on an average trading volume of 3,318 shares, the short-interest ratio is presently 2.3 days.

enGene Stock Up 18.6%

Shares of ENGNW stock traded up $0.40 on Friday, hitting $2.55. 2,123 shares of the stock were exchanged, compared to its average volume of 20,954. enGene has a one year low of $0.51 and a one year high of $4.20. The firm’s 50 day moving average is $3.10 and its two-hundred day moving average is $2.29.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.